NGNE 241115 40.00C (NGNE241115C40000) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

NGNE241115C40000

Watchlist

0.00
0.000.00%

15min DelayClose Oct 31 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

William Blair Maintains Neurogene(NGNE.US) With Buy Rating
Moomoo NewsOct 22 05:33 ET · Ratings
Neurogene's (NASDAQ:NGNE) Earnings Might Be Weaker Than You Think
Yahoo FinanceAug 17 10:01 ET
BMO Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $65
Moomoo NewsAug 14 07:34 ET · Ratings
Buy Rating for Neurogene: Promising Rett Syndrome Program and Strong Financial Outlook
TipRanksAug 14 07:25 ET · Ratings
Buy Rating Affirmed for Neurogene Amid Promising Outlook for Gene Therapy Candidate NGN-401
TipRanksAug 13 09:49 ET · Ratings
Neurogene's NGN-401 Wins Key FDA Designation
TipRanksAug 12 09:43 ET

Comments

Jaguar8

Apr 22 15:37

$Neurogene (NGNE.US)$
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...